Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study

Peer Review reports

Original Submission
11 Nov 2020	Submitted	Original manuscript
25 Nov 2020	Author responded	Author comments - Kazutaka Hosoya
Resubmission - Version 2
25 Nov 2020	Submitted	Manuscript version 2
16 Jan 2021	Reviewed	Reviewer Report
23 Jan 2021	Reviewed	Reviewer Report
22 Feb 2021	Author responded	Author comments - Kazutaka Hosoya
Resubmission - Version 3
22 Feb 2021	Submitted	Manuscript version 3
23 Feb 2021	Reviewed	Reviewer Report
8 Mar 2021	Reviewed	Reviewer Report
11 Mar 2021	Author responded	Author comments - Kazutaka Hosoya
Resubmission - Version 4
11 Mar 2021	Submitted	Manuscript version 4
13 Mar 2021	Author responded	Author comments - Kazutaka Hosoya
Resubmission - Version 5
13 Mar 2021	Submitted	Manuscript version 5
Publishing
16 Mar 2021	Editorially accepted
1 Apr 2021	Article published	10.1186/s12885-021-08048-4

Back to article page